NASDAQ:VSTM - Verastem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.17 -0.06 (-2.69 %)
(As of 04/19/2019 11:03 AM ET)
Previous Close$2.23
Today's Range$2.1491 - $2.2897
52-Week Range$2.13 - $10.35
Volume1.99 million shs
Average Volume2.70 million shs
Market Capitalization$160.31 million
P/E RatioN/A
Dividend YieldN/A
Beta3.03
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.72 million
Book Value$1.68 per share

Profitability

Net Income$-72,430,000.00

Miscellaneous

Employees169
Market Cap$160.31 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) issued its quarterly earnings data on Tuesday, March, 12th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.23. The biopharmaceutical company earned $1.21 million during the quarter, compared to analyst estimates of $5.56 million. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

7 equities research analysts have issued 1-year price objectives for Verastem's shares. Their forecasts range from $5.00 to $17.00. On average, they expect Verastem's share price to reach $12.1429 in the next year. This suggests a possible upside of 459.6% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

Has Verastem been receiving favorable news coverage?

News stories about VSTM stock have trended positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verastem earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.

Are investors shorting Verastem?

Verastem saw a decline in short interest in March. As of March 29th, there was short interest totalling 16,839,750 shares, a decline of 30.4% from the March 15th total of 24,185,220 shares. Based on an average daily trading volume, of 2,899,002 shares, the days-to-cover ratio is currently 5.8 days. Approximately 24.8% of the shares of the company are short sold. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Richard H. Aldrich Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta, Co-Founder
  • Dr. Michelle Dipp, Co-Founder (Age 43)

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $2.17.

How big of a company is Verastem?

Verastem has a market capitalization of $160.31 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.

What is Verastem's official website?

The official website for Verastem is http://www.verastem.com.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  410 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  711
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel